A PYMNTS Company

Bayer To Buy Women’s Health Biotech For $875M

By  |  August 11, 2020

Bayer struck an US$875 million deal to acquire British women’s health biotech Kandy Therapeutics, bolstering its pharmaceuticals division before patents expire on some key products.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    The German drug and chemical company agreed to pay US$425 million upfront and potential milestone payments of US$450 million until the launch of Kandy’s experimental treatment for menopause symptoms, reported Bloomberg. 

    Kandy’s drug NT-814 is expected to start a final-stage clinical trial next year and could generate peak sales of €1 billion (US$1.17 billion) globally, Bayer said Tuesday, August 11, in a statement. Bayer rose as much as 1.8% in Frankfurt.

    Full Content: Bloomberg

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.